AstraZeneca will face a “substantial setback” if its most ambitious foray into cutting edge immunotherapy falls flat, its chief executive Pascal Soriot has acknowledged.
The eagerly awaited study into a new lung cancer drug is expected to produce its first results within weeks.
> Read the full article on the Financial Times website
By Sarah Neville and David Crow
Source: Financial Times
The appointment makes Tuyen Ong the latest in a series of new CEO-partners hired by Flagship. Flagship Pioneering has named Tuyen Ong as CEO-partner. The new role sees the ex-Biogen […]
The COVID-19 pandemic has millennials worried—and that has them planning to buy more prescription drugs in the future, new research finds. WPP’s global media group, Mindshare, began surveying consumers in […]
AstraZeneca has received an investment of approximately $486m from the US Government to develop and supply its long-acting antibody (LAAB) cocktail, AZD7442, for Covid-19 treatment. AstraZeneca has received an investment […]